Grifols FY2021
-
Jeg vil lige omtale en aktie, der vist aldrig er blevet naevnt her paa forum. Det drejer sig om spanske Grifols, der arbejder med blodplasma. Virksomheden er noteret i Madrid ($GRF.MC) og New York ($GRFS). En af deres stoerste konkurrenter er australske CSL.
Det er endnu en gaeldstynget virksomhed, men jeg mener, at de har potentialet til at reducere deres gaeld. I mine oejne burde de halvere deres udbytte fra 8% til 4%, hvis de mener det alvorligt, at reduktion af gaelden er en prioritet. Hvis de skaerer udbyttet med 50-100%, saa synes jeg den er attraktiv til den nuvaerende kurs.
De er vurderet til BB- hos Fitch:
https://www.fitchratings.com/research/corporate-finance/fitch-assigns-grifols-sa-first-time-bb-idr-outlook-stable-27-09-2021Finansielle resultater:
https://www.grifols.com/en/financial-results
-
Grifols jumps on report on takeover speculation
https://seekingalpha.com/news/3818911-grifols-jumps-on-report-on-takeover-speculation
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind